Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 08, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share allocation notifications.
Material Changes
No material changes to financial performance or operations are reported. The filing details specific increases in the notional allocation of GSK Ordinary Share ADRs for named executives following a re-valuation of the cash element within the Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports compliance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) regarding share transactions.
Important Facts for Investors
- Transactions involve notional allocations of Ordinary Share ADRs within the US Retirement Savings Plan.
- Allocations occurred on November 2, 2006, at a price of $53.93 per share, and on November 3, 2006, at a price of $53.30 per share.
- Named recipients include Dr. JP Garnier, Dr. MM Slaoui, Dr. F Calhoun, Dr. R Greig, Mr. D Phelan, Dr. D Pulman, Mr. D Stout, and Mr. C Viehbacher.
- The report was signed by Victoria Whyte as the Authorised Signatory on November 08, 2006.